Boutros Marc, Moujaess Elissar, Kourie Hampig Raphael
Faculty of Medicine, Saint Joseph University of Beirut, Lebanon.
Department of Hematology and Oncology, Hotel Dieu de France University Hospital, Beirut, Lebanon.
Crit Rev Oncol Hematol. 2021 Nov;167:103273. doi: 10.1016/j.critrevonc.2021.103273. Epub 2021 Mar 15.
COVID-19 was declared a "Public Health Emergency of International Concern" in March 2020. Since then, drastic measures were implemented to reduce the virus spread. These measures prevented cancer patients from receiving prompt medical care. A delay in testing and treating cancer patients is thought to protect them from serious COVID-19 complications but exposes them at the same time to the risk of disease progression and cancer related mortality. Healthcare providers are therefore facing the dilemma of choosing between two unpleasant scenarios. To shed light upon the matter, we present in this review article, based on an extensive search of the literature, an overview of the delay in the management of cancer patients, possible contributors to this delay and its benefits and risks on cancer patients' health.
2020年3月,新型冠状病毒肺炎(COVID-19)被宣布为“国际关注的突发公共卫生事件”。自那时起,为减少病毒传播实施了严厉措施。这些措施导致癌症患者无法及时获得医疗救治。推迟对癌症患者的检测和治疗,虽被认为可保护他们免受COVID-19严重并发症的影响,但同时也使他们面临疾病进展和癌症相关死亡的风险。因此,医疗服务提供者面临着在两种不利情况之间做出选择的困境。为阐明这一问题,在这篇综述文章中,我们在广泛检索文献的基础上,概述了癌症患者管理的延迟情况、造成这种延迟的可能因素及其对癌症患者健康的益处和风险。